Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nathan H Leisenring"'
Autor:
Mark Chen, Eric S. Xu, Nathan H. Leisenring, Diana M. Cardona, Lixia Luo, Yan Ma, Andrea Ventura, David G. Kirsch
Publikováno v:
Sarcoma, Vol 2019 (2019)
Myxoid liposarcoma is a malignant soft tissue sarcoma characterized by a pathognomonic t(12;16)(q13;p11) translocation that produces a fusion oncoprotein, FUS-CHOP. This cancer is remarkably sensitive to radiotherapy and exhibits a unique pattern of
Externí odkaz:
https://doaj.org/article/3620b1399f0444b9a45ef2a13d3b660c
Autor:
David G. Kirsch, Ian J. Davis, Eric Xu, Warren Floyd, Andrea R. Daniel, Nathan H. Leisenring, Ian C. Lock, Joseph P. Foster, Mark Chen
Supplementary data figures, tables, and methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2e95ddf3c1bf741cda632f839cd4143
https://doi.org/10.1158/0008-5472.22428877.v1
https://doi.org/10.1158/0008-5472.22428877.v1
Autor:
David G. Kirsch, Ian J. Davis, Eric Xu, Warren Floyd, Andrea R. Daniel, Nathan H. Leisenring, Ian C. Lock, Joseph P. Foster, Mark Chen
Chromosomal translocations generate oncogenic fusion proteins in approximately one-third of sarcomas, but how these proteins promote tumorigenesis is not well understood. Interestingly, some translocation-driven cancers exhibit dramatic clinical resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d14a2b022f7bf1f62e44b2e90f2c9bd7
https://doi.org/10.1158/0008-5472.c.6513181.v1
https://doi.org/10.1158/0008-5472.c.6513181.v1
Autor:
Joseph P. Foster, Eric S. Xu, Warren Floyd, Ian J. Davis, Nathan H Leisenring, David G. Kirsch, Mark Chen, Andrea R. Daniel, Ian C. Lock
Publikováno v:
Cancer Res
Chromosomal translocations generate oncogenic fusion proteins in approximately one-third of sarcomas, but how these proteins promote tumorigenesis is not well understood. Interestingly, some translocation-driven cancers exhibit dramatic clinical resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069171f30adbb257f2ba5b675f75cc03
https://doi.org/10.1158/0008-5472.can-20-1497
https://doi.org/10.1158/0008-5472.can-20-1497
Autor:
Rami N. Al-Rohil, Nathan H Leisenring, Stacy Telloni, Jennifer L Rogers, Parisa Mansoori, Anne L. Marano
Publikováno v:
Journal of Drugs in Dermatology. 19:544-546
Novel oral anticoagulant (NOAC) medications have revolutionized hematology and cardiology. Recently, NOACs have demonstrated additional promise in dermatology. Specifically, rivaroxaban, a direct factor Xa inhibitor NOAC, has been shown to be success
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e312056da16b8fe38720c35ef97e231b
https://doi.org/10.36849/jdd.2020.10.36849/jdd.2020.4684
https://doi.org/10.36849/jdd.2020.10.36849/jdd.2020.4684
Publikováno v:
Journal of cutaneous pathologyREFERENCES. 49(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3056ad8c7814252a4bd2e024fe6131
https://pubmed.ncbi.nlm.nih.gov/33470458
https://pubmed.ncbi.nlm.nih.gov/33470458
Autor:
Nathan H, Leisenring, Jennifer L, Rogers, Stacy, Telloni, Parisa, Mansoori, Rami N, Al-Rohil, Anne L, Marano
Publikováno v:
Journal of drugs in dermatology : JDD. 19(5)
Novel oral anticoagulant (NOAC) medications have revolutionized hematology and cardiology. Recently, NOACs have demonstrated additional promise in dermatology. Specifically, rivaroxaban, a direct factor Xa inhibitor NOAC, has been shown to be success
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d346936c61f033bee20b1ac25889eda1
https://pubmed.ncbi.nlm.nih.gov/32484618
https://pubmed.ncbi.nlm.nih.gov/32484618
Autor:
Mark Chen, Andrea R. Daniel, Eric S. Xu, David G. Kirsch, Joseph P. Foster, Warren Floyd, Nathan H Leisenring, Ian C. Lock, Ian J. Davis
SummaryChromosomal translocations generate oncogenic fusion proteins in approximately one-third of sarcomas, but how these proteins promote tumorigenesis and the effect of cancer therapies on their function are not well understood. Here, we reveal a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b411dccaf36d14a1b417f2c0e147b86b
Publikováno v:
Cancer Research. 79:4512-4512
TP53 is the most frequently mutated gene in human cancer. Classically, p53-mediated tumor suppression is thought to occur via transactivation of canonical targets that induce cell cycle arrest and apoptosis. However, this model has been challenged by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c3d1b813bf8845069aa8bc4b3d35d2b
https://doi.org/10.1158/1538-7445.am2019-4512
https://doi.org/10.1158/1538-7445.am2019-4512
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 197(1)
Cancer immunotherapies are increasingly effective in the clinic, especially immune checkpoint blockade delivered to patients who have T cell–infiltrated tumors. Agonistic CD40 mAb promotes stromal degradation and, in combination with chemotherapy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1d82ac8aa9050e9d7e2e3879c15350
https://pubmed.ncbi.nlm.nih.gov/27217585
https://pubmed.ncbi.nlm.nih.gov/27217585